Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Genomic Health Inc (GHDX) Com Stk USD0.0001

Sell:$70.11 Buy:$70.16 Change: $0.43 (0.61%)
NASDAQ:0.83%
Market closed |  Prices as at close on 18 October 2019 | Switch to live prices |
Sell:$70.11
Buy:$70.16
Change: $0.43 (0.61%)
Market closed |  Prices as at close on 18 October 2019 | Switch to live prices |
Sell:$70.11
Buy:$70.16
Change: $0.43 (0.61%)
Market closed |  Prices as at close on 18 October 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Genomic Health, Inc. is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company's Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test. Its research and development activities are focused on developing a pipeline of tests to optimize the treatment of various cancers including breast, colon, prostate and other cancers. It offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS), and a Genomic Prostate Score, for prostate cancer.

Contact details

Address:
301 Penobscot Dr
REDWOOD CITY
94063-4700
United States
Telephone:
+1 (650) 5569300
Website:
www.genomichealth.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
GHDX
ISIN:
US37244C1018
Market cap:
$2.65 billion
Shares in issue:
37.55 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Kimberly Popovits
    Chairman of the Board, President, Chief Executive Officer
  • Gordon Cole
    Chief Financial Officer
  • Frederic Pla
    Chief Operating Officer
  • Steven Shak
    Chief Scientific Officer
  • Laura Kammeyer
    Chief Communications Officer
  • Kim McEachron
    Chief People Officer
  • James Vaughn
    Chief U.S. Commercial Officer
  • Jason Radford
    Chief Legal Officer and Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.